Compare CVS Health Corp (CVS) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Zeta Global Holdings Corp — how do they compare? CVS Health Corp trades at $86.16 (market cap $112.29B), while Zeta Global Holdings Corp trades at $33.09 (market cap $8.29B). The key difference: CVS Health Corp is far larger — about 13.5× Zeta Global Holdings Corp's market cap, and CVS Health Corp pays a 3.03% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Zeta Global Holdings Corp for 19 Days on average.
| CVS | ZETA | |
|---|---|---|
Market Cap | $112.29B | $8.29B |
Volume | 7,763,676 | 7,156,795 |
Sector | Health | Technology |
52-Week High | $110.60 | $33.74 |
52-Week Low | $70.08 | $14.55 |
Typical Hold Time | 83 Days | 19 Days |
Enterprise Value | $174.64B | $8.18B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, down 0.17% with a bearish technical signal. The company shows strong revenue growth to $402.1B in 2025 and has beaten earnings estimates for three consecutive quarters. Analyst consensus is overwhelmingly bullish with 85% buy ratings and a $111.20 price target representing 27% upside. Recent news highlights Aetna's 2027 Medicare plan enhancements and quarterly dividend declarations.
CVS presents a compelling value opportunity with attractive valuation metrics (P/E 23.17, P/S 0.27) and strong analyst support. Key risks include reimbursement pressure, regulatory scrutiny from ongoing investigations, and declining net margins. The stock's current technical weakness contrasts with solid fundamentals and positive earnings momentum.
ZETA trades at $33.03, down 2.1% today but remains near its 52-week high. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Revenue growth is accelerating with 2026 projections at $1.6B, though the company remains unprofitable with a -0.14% net margin. Recent expansion into the UK and AI platform growth are driving investor optimism.
ZETA presents a growth story with improving fundamentals but carries profitability risks. Analyst consensus is strongly bullish with a $35 price target representing 6% upside. Key risks include negative cash flow, high valuation multiples, and competitive pressure in the AI sector. The stock's current technical overbought condition suggests potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
